Real-world comparison of anti-CD20 therapies: efficacy, infections, and immune profiles in a German cohort - Takeaways - MDSpire

Real-world comparison of anti-CD20 therapies: efficacy, infections, and immune profiles in a German cohort

  • By

  • Jakob Stögbauer

  • Moritz Bewarder

  • Linda Groß

  • Lorenz Thurner

  • Klaus Fassbender

  • Rebecca Urschel

  • Einar A. Høgestøl

  • Gro O. Nygaard

  • Hanne F. Harbo

  • Olaf Stüve

  • Marc Pawlitzki

  • Sven G. Meuth

  • Martina Sester

  • Sergiu Groppa

  • Mathias Fousse

  • May 12, 2026

  • 0 min

Share

  • 1

    The study analyzed 262 patients treated with ocrelizumab, ofatumumab, or rituximab over a median of 36 months for neuroimmunological diseases.

  • 2

    Ocrelizumab and ofatumumab demonstrated low annual relapse rates of 0.11 and 0.08, respectively, indicating effective B-cell depletion.

  • 3

    Ofatumumab was associated with significantly lower infection rates compared to rituximab, highlighting differences in safety profiles.

  • 4

    Rituximab patients experienced hypogammaglobulinemia more frequently and earlier than those treated with ocrelizumab or ofatumumab.

  • 5

    The findings suggest that while B-cell depletion is effective, variations in immune responses and infection risks should guide individualized treatment strategies.

Original Source(s)

Real-world comparison of anti-CD20 therapies: efficacy, infections, and immune profiles in a German cohort

  • by Jakob Stögbauer, Moritz Bewarder, Linda Groß, Lorenz Thurner, Klaus Fassbender, Rebecca Urschel, Einar A. Høgestøl, Gro O. Nygaard, Hanne F. Harbo, Olaf Stüve, Marc Pawlitzki, Sven G. Meuth, Martina Sester, Sergiu Groppa, Mathias Fousse

  • May 12, 2026

Related Content

Oxidized mannan-MOG35-55 conjugate as a basis for targeted immune modulation in multiple sclerosis

Associations of Serum Alpha-Linolenic Acid with Disability and Brain Volume in Multiple Sclerosis: A Concise Replication Study

An Oxidative Glial Profile as a Predictor of Disability and Cognitive Decline in Primary Progressive Multiple Sclerosis